David Radspinner
Chief Executive Officer Vinta Bio
Seminars
Wednesday 25th March 2026
Unlocking Scalability: Innovative Advances in Adherent Manufacturing for Gene Therapies
9:50 am
- Exploring how an innovative, validated process leveraging fixed-bed bioreactors with the option to integrate perfusion technology is advancing adherent manufacturing for gene therapies
- Gaining deeper insights into cell line kinetics and optimizing viability, health, and harvest timing – a level of process control often difficult to achieve with traditional suspension batch methods
- Discovering how this approach translates into cleaner upstream material, higher product volumes, and improved full capsid percentages for AAV viral vectors
- Learning how these advancements enable faster development, more efficient manufacturing, and higher quality products, ultimately accelerating market access for gene therapies, particularly for rare diseases
Thursday 26th March 2026
Panel Discussion: Surveying Current Investor Sentiment in Gene Therapy to Strengthen Your Funding Strategy
9:00 am
- Understanding what drives interest and what’s driving hesitation across the field
- Discussing the role of policy, regulation, and public trust in shaping long-term investment
- Reviewing the various sources of funding that exist for companies beyond VCs
